Last Updated : May 4, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Simponi I.V. | Golimumab | Arthritis, rheumatoid | List with criteria/condition | Complete | ||
| Actemra | Tocilizumab | Arthritis, rheumatoid | List with criteria/condition | Complete | ||
| Xeljanz | Tofacitinib | Arthritis, rheumatoid | List with criteria/condition | Complete | ||
| Simponi | Golimumab | Arthritis, Rheumatoid | List in a similar manner | Complete | ||
| Cimzia | Certolizumab pegol | Arthritis, rheumatoid | Do not list | Complete | ||
| Orencia | Abatacept | Arthritis, Rheumatoid | List in a similar manner | Complete | ||
| Actemra | Tocilizumab | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete | ||
| Humira | Adalimumab | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete | ||
| Rituxan | Rituximab | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete | ||
| Orencia | Abatacept | Arthritis, Rheumatoid | List with clinical criteria and/or conditions | Complete |
Last Updated : May 4, 2024